Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Royalty revenues payable

Royalty revenues payable at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$7.27M+85.6%
HTF
Heartflow, Inc. Common StockHTFL
$568K+37.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$11.69M-9.3%
Ondas, Inc. logo
Ondas, Inc. ONDS
$85.5K+23.5%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$29.31M+274%
HTF
Heartflow, Inc. Common StockHTFL
$568K+37.2%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:RoyaltyRevenuesPaidAndPayable.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's royalty revenues payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's royalty revenues payable?
BioCryst Pharmaceuticals (BCRX) reported royalty revenues payable of -$31.48M in Q1 2026.
How has BioCryst Pharmaceuticals's royalty revenues payable changed year-over-year?
BioCryst Pharmaceuticals's royalty revenues payable decreased by 19.6% year-over-year, from -$26.33M to -$31.48M.
What does royalty revenues payable mean?
This represents the total financial obligations owed to third parties based on the generation of royalty-bearing revenue. It reflects the cost of licensing intellectual property or technology essential to the company's product portfolio. Tracking this provides insight into the company's reliance on external innovation and the associated margin impact.